Fibrinolytic system components

The fibrinolytic system is a complex biological pathway primarily responsible for the dissolution of fibrin clots to maintain vascular patency (StatPearls, 2023). Its central mechanism involves the conversion of the inactive proenzyme plasminogen into the active serine protease plasmin (Cesarman-Maus & Hajjar, 2005). This conversion is mediated by specific activators, most notably tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) (Chapin & Hajjar, 2015). Once activated, plasmin enzymatically degrades the fibrin matrix of a blood clot into soluble fibrin degradation products, such as D-dimer (NIH, 2022). The system is tightly regulated by inhibitors like plasminogen activator inhibitor-1 (PAI-1) and alpha 2-antiplasmin to prevent excessive or systemic proteolysis (UniProt, 2024). Clinical relevance is high in cardiovascular diseases, where thrombolytic drugs like alteplase are used to treat acute myocardial infarction and ischemic stroke by mimicking natural activators. Conversely, antifibrinolytic agents like tranexamic acid are employed to reduce bleeding by competitively inhibiting plasminogen activation (StatPearls, 2023). Beyond hemostasis, components of this system play significant roles in tissue remodeling, wound healing, and tumor metastasis (Cesarman-Maus & Hajjar, 2005). Dysregulation of these components can lead to either life-threatening thrombosis or severe hemorrhagic disorders.

Other names

Plasminogen systemFibrinolysis pathwayThrombolytic system

Activation of plasminogen to plasmin to catalyze the degradation of fibrin clots (thrombolysis), or the competitive inhibition of plasminogen activation and plasmin activity to prevent clot dissolution (antifibrinolysis).